Searched for
CIPLA GROUP
These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...- Nifty in control of FIIs? The unlucky 13 bluechips facing the hardest institutional selloffForeign investors have significantly reduced holdings in many Nifty companies since September 2024. This has impacted top blue-chip stocks,...
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...
- Bonus issues, dividends and more: Reliance Industries, Trent among 20 stocks turning ex-date this weekReliance Industries, Trent, and 18 other stocks are set to turn ex-date this week for corporate actions including dividends and bonus issue...
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Strong revenue growth fails to shield India Inc margins in March quarterCorporate India's March 2026 quarter results showed a mixed performance. While revenues grew strongly, input cost inflation and a weaker ru...
- Is India Inc's CSR truly driving systemic change or just shifting funds?Corporate India is entering a new phase of CSR. Spending is expected to cross ₹1.2 lakh crore by 2035. Companies are shifting towards syste...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Cohance Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surgeCohance Lifesciences shares surged over 43% in two days following the appointment of former Cipla CEO Umang Vohra as Executive Chairman and...
- Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang VohraShares of Cohance Lifesciences surged 20% on Monday after the appointment of former Cipla CEO Umang Vohra as its new Executive Chairman and...
- Pharma stocks buck market weakness as Dr Reddy's gainsPharma stocks showed strength on Thursday, defying market weakness. Dr Reddy's Laboratories saw significant gains, fueled by anticipation o...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cipla tanks 5% as promoters sell stake in block dealDr Y K Hamied, Chairman and MK Hamied, Vice Chairman who are Non-Executive Directors and promoters, have sold 2,01,69,756 shares, represent...
- Cipla forms JV with Jiangsu Acebright for respiratory medicines in ChinaThe agreement is between Chinese firm Jiangsu Acebright and Cipla's European arm, Cipla EU for a combined investment of USD 30 million, as ...
- Stempeutics research gets DCGI nod for stem cell based productThe company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.
- Post Invagen sale, Hetero says to strengthen US operationsCipla said the group, through its subsidiary Camber Pharmaceuticals Inc., will continue to strengthen its operations in the US.
- Cipla looking to expand contraceptive pills business; in talks with International Planned ParenthoodThe country's second-largest pharmaceuticals company, Cipla, is in talks with an international health group to expand its contraceptive pil...
- Cipla makes cancer drug cheaperCipla has launched a copycat version of German pharma company Bayer’s cancer medicine Nexavar at one-tenth the price.
- Reliance, Cipla in talks for retail pactIf the deal is sealed, Cipla will supply generic pharmaceutical products to Reliance Retail.
Load More
